Extracellular Vesicle - MDM2-DNA as a Potential Liquid Biopsy Biomarker for Disease Identification in Retroperitoneal Liposarcoma.

Autor:	Calore F; The Ohio State University, Department of Cancer Biology and Genetics, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Casadei L; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Sarchet PD; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Fadda P; The Ohio State University Comprehensive Cancer Center, Genomics Shared Resources, Columbus, OH, USA., Nigita G; The Ohio State University, Department of Cancer Biology and Genetics, Columbus, OH, USA., Coombes KR; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; Medical College of Georgia, Department of Population Health Sciences, Georgia Cancer Center at Augusta University, Augusta, GA., Cascione L; Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana (USI), Bellinzona, Switzerland, Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland., Costas C de Faria F; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Tahara S; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Iwenofu OH; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Pollock RE; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Grignol VP; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Jazyk:	angličtina
Zdroj:	Annals of surgery [Ann Surg] 2024 May 21. Date of Electronic Publication: 2024 May 21.
DOI:	10.1097/SLA.0000000000006345
Abstrakt:	Objective: We aimed to assess the levels of MDM2-DNA within extracellular vesicles (EVs) isolated from the serum of retroperitoneal liposarcoma (RLS) patients versus healthy donors, as well as within the same patients at the time of surgery versus post-operative surveillance visits. To determine whether EV-MDM2 may serve as a possible first-ever biomarker of liposarcoma recurrence. Background: A hallmark of well-differentiated and de-differentiated (WD/DD) retroperitoneal liposarcoma is elevated MDM2 due to genome amplification, with recurrence rates of >50% even after complete resection. Imaging technologies frequently cannot resolve recurrent WD/DD-RLS versus postoperative scarring. Early detection of recurrent lesions, for which biomarkers are lacking, would guide surveillance and treatment decisions. Methods: WD/DD-RLS serum samples were collected both at the time of surgery and during follow-up visits from 42 patients, along with sera from healthy donors (n=14). EVs were isolated, DNA purified and MDM2-DNA levels determined through q-PCR analysis. Non-parametric tests were employed to compare EV-MDM2 DNA levels from patients versus control group, as well as the time of surgery versus post-surgery conditions. Results: EV-MDM2 levels were significantly higher in WD/DD-RLS than controls (P= 0.00085). Moreover, EV-MDM2 levels were remarkably decreased in WD/DD-RLS patients after resection (P=0.00036), reaching values comparable to control group (P=0.124). During post-operative surveillance, significant increases of EV-MDM2 was observed in some patients, correlating with CT scan evidence of recurrent or persistent post-resection disease. Conclusions: Serum EV-MDM2 may serve as a potential biomarker of early recurrent or post-operatively persistent WD/DD-RLS, a disease currently lacking such determinants. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu